Clinical Trial Update: MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study comparing MLN0128 to sorafenib in advanced or metastatic hepatocellular carcinoma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• MLN0128 (sapanisertib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Kathy Miller | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-03-31